
Index

Page references in *italics* indicate figures, and those in **bold** indicate tables.

- 3 α -acetamino-23,24-bisnor-5 α -cholane,
synthesis of 177–179
- acetophenone
asymmetric hydrogenation of 120–121
reduction with *Geotrichum candidum*
93–97
reduction using [(*S*)-XYL-TetraPHEMP
RuCl₂ (*S,S*)-DPEN] as a precatalyst
111–113
titanocene-catalyzed reduction of
acetophenone in the presence of water
98–99
- N*-acetyl-2-butyldole, catalytic
asymmetric hydrogenation of 82–84
- activated ketones, *N*-arenesulfonyl- and
N-alkylsulfamoyl-1,2-
diphenylethylenediamine ligands for
ruthenium-catalyzed asymmetric
transfer hydrogenation of 113–116
- alcohols
alcohol **6**, oxidation of 220–221
oxidation of primary and secondary
183–192
synthesis via free-radical chemistry
97–100
- aldehydes, proline catalyzed α -
aminoxylation of 194–199
- Aliskiren **6**, **7**
- alkenes
asymmetric epoxidation **210**
asymmetric hydrogenation of 35–86
- heterocyclic phosphino oxazoline
(HetPHOX) iridium complexes for the
asymmetric hydrogenation of 48–55
phosphinite oxazoline iridium complexes
for the asymmetric hydrogenation of
42–48
reduction of 10
Ru/Silia* Cat*TEMPO(c)-mediated
oxidation of alkenes to α -hydroxyacids
199–204
SYNPHOS and DIFLUORPHOS as
ligands for ruthenium-catalyzed
hydrogenation of ketones and
125–132
trisubstituted alkene reduction *10*
- 2-(2-alkenyl)phenols, VO(acac)₂/TBHP
catalyzed epoxidation of 211–214
- 7-alkoxy-1-naphthols, catalytically
oxidative coupling by chiral vanadium
complexes 271–272
- N*-alkylsulfamoyl-1,2-
diphenylethylenediamine ligands, for
ruthenium-catalyzed asymmetric
transfer hydrogenation of activated
ketones 113–116
- allyl alcohols
reduction of 10
Sharpless chiral epoxidation of **23**
- α -alkoxy substituted acids **8**
 α -alkyl substituted acids **6–7**, **8**
 α -amino acids **4**, **5**

- Amadori rearrangement 215–216
- amines 25
- amino keto ester compound, *syn*-selective DKR of 15
- (*S*)-3-amino-1-phenyl-1-propanol 153
- (*R*)-3-amino-1-phenyl-propan-1-ol, synthesis of 155–156
- 3 α -amino-23,24-bisnor-5 α -cholane, stereoselective synthesis via reductive amination 175–181
- aminoalcohol **5**, phosgene cyclization of 218–219
- 3 α -*N*-1-[*N*(3-[4-aminobutyl])1,3-diaminopropane]-23,24-bisnor-5 α -cholane, synthesis of 179–181
- α -aminooxylation, of aldehydes and ketones 194–199
- (*R*)-7-anilinoxy-1,4-dioxaspiro[4.5]decan-8-one, synthesis of 196–199
- (*R*)-2-anilinoxypropanol, synthesis of 195–196
- arabinose-derived ulose 204–210
- arene ruthenium complex, with polymerizable side chains for the synthesis of immobilized catalysts 132–135
- N*-arenesulfonyl-1,2-diphenylethylenediamine ligands, for ruthenium-catalyzed asymmetric transfer hydrogenation of activated ketones 113–116
- N*-arenesulfonyl-1,2-diphenylethylenediamines, synthesis of 113–114
- aromatic ketones
asymmetric transfer hydrogenation of **144**
diphosphine RuCl₂ diamine catalyzed hydrogenation of simple 101–113
- arpromidines 10
- aryl methyl sulfides
asymmetric sulfoxidation with hydrogen peroxide in water 297–302
stereoselective catalytic oxidation of 300–302
- asymmetric Baeyer–Villiger oxidation, of 3-phenylcyclobutanone 261–263
- asymmetric epoxidation
catalyzed by novel azacrown ether-type chiral quaternary ammonium salts
under phase-transfer catalytic conditions 228–235
of (*E*)-chalcone catalyzed by the azacrown ether-type quaternary ammonium salt as chiral PTC 233–235
of phenyl-2-(3'-pyridylvinyl)sulfone using poly-leucine hydrogen peroxide gel 251–254
- asymmetric hydrogenation
of alkenes, enones, ene-esters and ene-acids 35–86
of methyl (*Z*)-2-acetamidocinnamate 64–65
of *trans*- α -methylstilbene 53–55
- asymmetric reduction, of ketones 87–159
- asymmetric transfer hydrogenation 150–151
of aromatic ketones **144**
of ethyl benzoylacetate 115–116
- asymmetric transfer hydrogenation (ATH) catalysts 15–20
general structure 16
for industrial application 16
- autoclave 83
- avir intermediate synthesis, by ketone hydrogenation 19
- asymmetric sulfoxidation, of aryl methyl sulfides with hydrogen peroxide in water 297–302
- azacrown ether
synthesis of 230–232
synthesis of precursor 229–230
azacrown ether-type quaternary ammonium salt, synthesis of 232–233
- Baeyer–Villiger oxidation
asymmetric oxidation of 3-phenylcyclobutanone 261–263
of ketones 27–28
- Bakers' yeast, reduction of unsaturated aldehydes 10–11
- Befloxatone 22
- benzenes, oxidative coupling with α,β -unsaturated aldehydes by Pd(OAc)₂/HPMoV/O₂ system 275–278
- (*R*)-2-(2-(benzo[1,3]dioxol-5-yl)ethyl)-1,2,3,4-tetrahydroquinoline, synthesis of 173–175

- (*R*)-benzyloxy(*tert*-butyl)methylphosphine–borane, synthesis of 67–69
- benzyl 4-bromobenzyl sulfide
oxidation to benzyl 4-bromobenzyl sulfone 286–288
oxidation to benzyl 4-bromobenzyl sulfoxide 284–285
- benzyl 4-bromobenzyl sulfone 286–288
- benzyl 4-bromobenzyl sulfoxide 284–285
- benzyl-4,6-*O*-isopropylidene- α -D-glucopyranoside, 2-deoxy-2-[[2-(hydroxy-3,5-di-*tert*-butylphenyl)methylene]imine]
as ligand for vanadium-catalyzed asymmetric oxidation of sulfides 293–296
synthesis of 294–295
- (4*S*,5*S*)-*O*-[1-benzyl-1-(5-methyl-2-phenyl-4,5-dihydro-oxazol-4-yl)-2-phenylethyl]-diphenylphosphinite, synthesis of 43–45
- (–)-bestatin 21, 22
- β -amino acid synthesis 6
- β -amino acids 5–6
- bicyclo[3.2.0]hept-2-en-6-one, oxidation of racemic 27
- BINAP-DPEN catalyst 13
- BINAPINE ligand 5, 6
- ((*R*)-BINAP)PtCl₂ complex, synthesis of 298
- [(*R*)-BINAP]Pt(μ OH)₂(BF₄)₂ complex, synthesis of 299
- binol-zinc complex 249–251
- biocatalysts, alcohol dehydrogenases and ketoreductases 21–24
- 3,3'-bis-(3,5'-bis-trifluoromethyl-phenyl)-2,2'-bismethoxymethoxy [1,1']-binaphthalene, synthesis of 165–166
- (*S*)-2,2'-bis[di(4-methoxy-phenyl)phosphinyl]oxy-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl
as ligand for rhodium-catalyzed asymmetric hydrogenation 36–41
synthesis of 38–40
- (*R,R*)-bis(diphenylphosphino)-1,3-diphenylpropane
synthesis of 91–93
as versatile ligand for enantioselective hydrogenations 89–93
- (*R,R*)-2,2'-bis[(*S*)-1-(diphenylphosphino)ethyl]1,1''-biferrocene, synthesis of 80–82
- (*R,R*)-2,2'-bis[(*S*)-1-(diphenylphosphinyl)ethyl]1,1''-biferrocene 78–80
- (*R,R*)-2,3-bis(*tert*-butylmethylphosphino)quinoxaline 70–71
as a ligand for rhodium-catalyzed asymmetric hydrogenation of prochiral amino acid and amine derivatives 65–73
- 3,5-bis(trifluoromethyl)acetophenone 14
- 3,5-bis(trifluoromethyl)phenyl ethanol 21
- (*R*)-3,3'-[3,5-bis(trifluoromethyl)phenyl]₂-1,1'-binaphthylphosphate, synthesis of 166–167
- borane reagents, modified 20
- Brønsted acid catalyzed enantioselective reduction, of methyl-aryl ketimines 168, **169**
- 3-bromo-2,6-dimethoxy-4-di(3,5-dimethylphenyl)phosphinopyridine, synthesis of 57–58
- 3-bromo-2,6-dimethoxy-4-di(3,5-dimethylphenyl)phosphinoylpyridine, synthesis of 59
- 3-bromo-2,6-dimethoxypyridine, synthesis of 55–56
- Brønsted acid catalyzed transfer hydrogenation, metal-free 170–175
- BrXuPHOS, synthesis and application of 116–121
- (*S*)-BrXuPHOS, synthesis of 117–119
- (*S,S,SS*)-BrXuPHOS-Ru-DPEN, synthesis of 119–120
- (4*S*)-*tert*-butyl-2-(3-diphenylphosphinothiophene-2-yl)-4,5-dihydrooxazole, synthesis of 50–51
- (4*S*)-*tert*-butyl-2-(thiophene-2-yl)-4,5-dihydrooxazole, synthesis of 49–50
- (*R*)-*tert*-butyl(hydroxymethyl)methylphosphine–borane, synthesis of 66–67
- t*-butylmethylketone 13

- (*S*)-*tert*-butylmethylphosphine–borane, synthesis of 69–70
- candoxatril intermediate, synthesis of 2 carbon-carbon double bonds, reduction of 3–12
- (1*S*,2*S*)-*N*-Boc-*N'*-(4-carboxymethoxybenzenesulfonyl)-1,2-diphenylethylenediamine 147
- catalytic asymmetric epoxidation, of α,β -unsaturated esters promoted by a yttrium-biphenyldiol complex 239–248
- catalytic asymmetric hydrogenation of 3-methyl-*N*-(*p*-toluenesulfonyl)indole 84–86
- of *N*-acetyl-2-butylandole 82–84
- catalytic enantioselective epoxidation of α,β -enones with a binol-zinc-complex 249–251
- of *trans*-disubstituted and trisubstituted alkenes with arabinose-derived ulose 204–210
- (*E*)-chalcone, asymmetric epoxidation catalyzed by the aza-crown ether-type quaternary ammonium salts as chiral PTC 233–235
- chiral Brønsted acids induced reductions 12
- chiral fluoxetine synthesis, using ATH 17
- chiral phase transfer catalysis (PTC) 25–26
- chiral phosphine ligands 3
- chiral sulfoxides 28–29
- 7-chloro-4-phenyl-1,2,3,4-tetrahydroquinoline, synthesis of 172
- α -chloro- β -ketoester, using engineered *E. coli* cells 22
- di- μ -chloro-bis[chloro(η^6 -1-isopropyl-4-methyl-benzene)ruthenium(II)], synthesis of 136
- 2-(4-chlorophenyl)-1,2-hydroxypropanoic acid, synthesis of 202–204
- 2-(4-chlorophenyl)-1,2-propandiol, synthesis of 201–202
- cinnamaldehyde, synthesis of 276–278
- (+)-citronellol 11
- (*D*)-codeinone, from (*D*)-dihydrocodeinone via the use of modified *O*-iodoxybenzoic acid 263–266
- codeinone, synthesis of 264–266
- copper (II) catalyzed oxidation, of primary alcohols to aldehydes with atmospheric oxygen 183–187
- copper (II) complex **1**, synthesis of 184–185
- Corey–Bakshi–Shibata (CBS) reagent 20
- (*S*)-2-cyano-1-phenyl-1-ethanol 152
- (4*S*,5*S*)-[η^4 -1,5-cyclooctadiene-{2-(2-phenyl-5-methyl-4,5-dihydro-oxazol-4-yl)-1,3-diphenyl-2-diphenylphosphinite-propane}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 45–46
- (4*S*)-[η^4 -1,5-cyclooctadiene]-{4-*tert*-butyl-2-(3-diphenylphosphino-thiophene-2-yl)-4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate, synthesis of 52–53
- α -dehydroamino acids, (*R*)-2,2',6,6'-tetramethoxy-bis[di(3,5-dimethylphenyl)phosphino]-3,3'-bipyridine [(*R*)-Xyl-P-Phos] as ligand for rhodium-catalyzed asymmetric hydrogenation of 55–65
- 3,3-diarylpropylamine 10
- (+) or (–)-2,3-*O*,*O'*-dibenzoyltartaric acid monohydrate 61–62
- dibenzylamine compound **4**, hydrogenation of 217–218
- 1-dibenzylamino-1-deoxy-D-fructose 215–216
- acetal protection of 216–217
- DIFLUORPHOS, as ligand for ruthenium-catalyzed hydrogenation of alkenes and ketones 125–132
- 3,3-diformyl-2,2'-biphenol, synthesis of 268–270
- (*D*)-dihydrocodeinone, (*D*)-codeinone from 263–266
- 2',3'-diisobutyl acetal, synthesis of 205–206
- diltiazem synthesis, using poly-leucine epoxidation 26

- dimethyl itaconate, asymmetric hydrogenation of 40–41
- 2-(3,7-dimethyl-octa-2,6-dienyl)-phenol
VO(acac)₂/TBHP catalyzed epoxidation of 212–213
VO(acac)₂/TBHP/TFA catalyzed oxidative cyclization of 213–214
- [1,(2,4-dimethyl-phenyl)-ethyl]-
(4-methoxy-phenyl)-amine, synthesis of 167–170
- [(*R*)-*N,N*-dimethyl(1-methyl)benzylamino-C²,N]-{*RAC*-4,4',6,6'-tetramethyl-2,2'-bis[bis(3,5-dimethylphenyl)phosphino]-biphenyl}-palladium (II) tetrafluoroborate 107–108
- (*R*)-2-[(*S*)-1-(dimethylamino)ethyl]-1-iodoferrocene, synthesis of 73–75
bis(3,5-dimethylphenyl)-(2-iodo-3,5-dimethylphenyl)phosphine oxide, synthesis of 103–104
bis(3,5-dimethylphenyl)phosphine chloride, synthesis of 56–57
tri(3,5-dimethylphenyl)phosphine oxide, synthesis of 102–103
(*R*)-3,3'-diiodo-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene, synthesis of 164
- dioxirane catalyzed epoxidation 23–24
(±)-1,2-diphenyl-1,2-ethylenediamine, synthesis of 137–138
- 2-[2-(diphenylphosphanyl)phenyl]7-isopropyl-6,7-dihydro-5*H*-1-pyridine 259–260
- 2-[2-(diphenylphosphinoyl)phenyl]7-isopropyl-6,7-dihydro-5*H*-1-pyridine 258–259
- (*R*)-2-[(*S*)-1-(diphenylphosphinyl)ethyl]-1-iodoferrocene, synthesis of 75–78
- (*S,S*)-1,3-diphenylpropane-1,3-diol, synthesis of 89–90
- diphosphine RuCl₂ diamine catalyzed hydrogenation, of simple aromatic ketones 101–113
- double ketoester reduction 22, 23
DSM MONOPHOS hydrogenation ligand system 7
Dual MagnumTM intermediate, Syngenta imine reduction 12–13
- dynamic kinetic resolution (DKR) processes 15
- elarofiban 5
- enantioselective epoxidation
of 1-phenyl-3,4-dihydronaphthalene 236–239
of olefins using phase transfer conditions 235–239
- enantioselective hydrogenations, (*R,R*)-bis(diphenylphosphino)-1,3-diphenylpropane as versatile ligand for 89–93
- ene-acids and ene esters, asymmetric hydrogenation of 35–86
- enone epoxidation, phase transfer catalysts 26
- enones, asymmetric hydrogenation of 35–86
- α,β -enones, catalytic enantioselective epoxidation with a binol-zinc-complex 249–251
- epoxidation, hydroxylation and related reactions 193–254
- epoxides, synthesis of enantiomerically enriched 226–228
- esomeprazole 28
(1*S*,2*S*)-*N*-[(4-ethoxycarbonyl)methoxybenzenesulfonyl]-1,2-diphenylethylene-diamine 146
(1*S*,2*S*)-*N*-Boc-*N'*-[(4-ethoxycarbonyl)methoxybenzenesulfonyl]-1,2-diphenylethylene-diamine 146–147
(*R*)-ethyl 3-hydroxy-3-phenylpropylcarbamate, synthesis of 156–157
- ethyl (4-chlorosulfonyl)phenoxyacetate 146
- ethyl benzoylacetate, asymmetric transfer hydrogenation 115–116
- ethyl chloroacetate, reduction of 22
- (*S*)-3-fluoro-1-phenylethanol, synthesis of 122–124
- α -fluorotroponone, synthesis of silica KG-60-supported enantiomerically enriched 225–226
- (*R*)-fluoxetine, synthesis of 158–159
(*S*)-fluoxetine 17

- (*S*)-fluoxetine hydrochloride 153–154
 preparation of 151–154
 formate dehydrogenase (NADH) 21
- Geotrichum candidum* 93–97
 cultivation of 94
 microbial reduction of ketones using
96, 97
- Glitazar API structures 8
 glucose dehydrogenase (NADPH) 21
- heterocyclic phosphino
 oxazoline(HetPHOX) iridium
 complexes, synthesis and application
 for the asymmetric hydrogenation of
 alkenes 48–55
- HIV treatment, anti-retroviral therapy with
 APIs 18
- β -homophenylalanine 5
- hydrogen peroxide in the presence of
 zirconium tetrachloride, selective
 oxidation of sulfides to sulfoxides and
 sulfones using 283–288
- hydrogenation, asymmetric hydrogenation
 of alkenes, enones, ene-esters and ene-
 acids 35–86
- 1-hydroxy-5-decanone, synthesis of
 189–192
- β -hydroxy- α -amino acids 15
- α -hydroxyacids, Ru/Silia Cat*TEMPO(c)-
 mediated oxidation of alkenes to
 199–204
- hydroxylation, epoxidation and related
 reactions 193–254
- (*7R*)-2-(2-hydroxyphenyl)-7-isopropyl-6,7-
 dihydro-5*H*-1-pyridine, synthesis of
 256–257
- imines
 catalytic hydrogenation of 12–15
 enantioselective reduction 162
 metal-free reduction of 162–170
 reduction and reductive amination
 161–181
- iminium salts 25
- immobilized catalysts, arene ruthenium
 complex with polymerizable side
 chains for the synthesis of
 132–135
- indoles, rhodium-catalyzed asymmetric
 hydrogenation of 73–86
- industrial catalysts, for regio- or stereo-
 selective oxidations and reductions
 1–33
- 2-iodoxybenzoic acid 188–192
- itaconic acids 4
- Juliá-Colonna method 26
- Katsuki–Sharpless epoxidation reaction 23
- ketimines
 Brønsted acid catalyzed enantioselective
 reduction of methyl-aryl 168, **169**
 general procedure for the transfer
 hydrogenation of 167
- β -keto nitriles, polymer-supported chiral
 sulfonamide catalyzed reduction of
 155–159
- ketones
 asymmetric reduction of 87–159
 Baeyer–Villiger oxidation of 27–28
 catalytic hydrogenation of 12–15
 [diphosphine RuCl₂ diamine]-catalyzed
 hydrogenation of simple aromatic
 101–113
 microbial reduction 93
N-arenesulfonyl- and *N*-alkylsulfamoyl-
 1,2-diphenylethylenediamine ligands
 for ruthenium-catalyzed asymmetric
 transfer hydrogenation of activated
 113–116
 organocatalytic α -hydroxylation of 27
 oxidation to lactones or enones
 255–266
 proline catalyzed α -aminooxylation of
 194–199
 ruthenium-catalyzed enantioselective
 reduction of 121–124
 SYNPHOS and DIFLUORPHOS as
 ligands for ruthenium-catalyzed
 hydrogenation of alkenes and
 125–132
 titanocene-catalyzed reduction of
 97–100
- KG-60-FT 225, 226, **227, 228**
- L-869, 298 intermediate synthesis 13, 14
 (*R*)-(+)-lansoprazole, synthesis of 288–290

- ligands
in situ formation of 121–124
- lilial, stereocontrolled synthesis via iridium catalytic reduction 10, 11
- Lilly Azar intermediate, formed by chiral hydrogenation 8
- Merck
 β -amino acid synthesis 6
ketone reduction 14
- (*S,S*)-methanesulfonyloxy-1,3-diphenylpropane-1,3-diol, synthesis of 91
- (*R*)-2,2'-bis-methoxymethoxy-[1,1']binaphthalene (MOM-BINOL), synthesis of 162–163
- methyl 2,2'-dihydroxy-1,1'-binaphthalene-3-carboxylate, synthesis of 273–275
- methyl (*E*)-3-acetylamino-2-butenolate, asymmetric hydrogenation of 71–73
- methyl phenyl sulfon, synthesis of 281–283
- methyl (*Z*)-2-acetamidocinnamate
asymmetric hydrogenation of 64–65
Rh-catalyzed asymmetric hydrogenation of derivatives of 65
- methyl (*Z*)- α -acetamido cinnamate, asymmetric hydrogenation of 41
- (4*S*,5*S*)-2-(5-methyl-2-phenyl-4,5-dihydrooxazol-4-yl)-1,3-diphenylpropan-2-ol, synthesis of 42–43
- (*R*)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfonyl]-1*H*-benzimidazole {(*R*)-(+)-lansoprazole}, synthesis of 288–290
- methyl-4-deuterio-4-phenyl-4-hydroxybutanoate, titanocene-catalyzed synthesis of 99–100
- $[\eta^6$ -(2-methyl-benzoic acid (2-(2-methylacryloyloxy)-ethyl ester)RuCl₂)₂], synthesis of 134–135
- 2-methyl-cyclohexa-2,5-dienecarboxylic acid 2-(2-methyl-acryloyloxy)-ethyl ester, synthesis of 133–134
- 3-methyl-*N*-(*p*-toluenesulfonyl)indole, catalytic asymmetric hydrogenation of 84–86
- (*S*)-3-methylamino-1-phenyl-1-propanol 153
- (*R*)-3-methylamino-1-phenylpropan-1-ol, synthesis of 157–158
- trans*- α -methylstilbene
asymmetric epoxidation using ulose as catalyst 208–210
asymmetric hydrogenation of 46–48, 53–55
- methylstilbene, asymmetric reduction of 10
- cis*- β -methylstyrene, asymmetric epoxidation of 222–224
- methylsulfonylbenzene (IUPAC), synthesis of 281–283
- modified borane reagents 20
- (\pm)-monotosylate-1,2-diphenyl-1,2-ethylenediamine 136–138
- 2-naphthol derivatives, catalytic oxidative cross-coupling reaction of 273–275
- naveglitazar 8
- neurokinin intermediate 28
- [NH₂Me₂][RuCl-(*S*)-DIFLUORPHOS]₂ [μ -Cl]₃, synthesis of 128–129
- [NH₂R₂][(RuCl(P*P))₂(μ -Cl)₃], synthesis of 127–128
- nitriles, asymmetric unsaturated nitrile reduction 9
- Novartis aliskiren, intermediate hydrogenation 6, 7
- Noyori *t*-butylmethylketone reduction 13
- Noyori tetralone reduction 13
- (*S*)-5,5',6,6',7,7',8,8'-octahydro-1,1'-bi-2-naphthol, synthesis of 37–38
- 2-octanol, dehydrogenation using Robinson's catalyst 187–188
- olefins
asymmetric epoxidation 224
enantioselective epoxidation of 235–239
oxazolidinone ketone catalyst for the asymmetric epoxidation of *cis*-olefins 215–224
- OPC-51803 7
- organocatalytic α -hydroxylation of ketones 27
- osmate exchanged Mg-Al layered double hydroxides, synthesis of 280–281

- oxaziridinium cations 235
- oxazoline ligands, for ketone hydrogenation 14
- oxidation 23–29
- of ketones to lactones or enones 255–266
 - of primary and secondary alcohols 183–192
 - of sulfides and sulfoxides 279–302
- oxidative C–C coupling 267–278
- of benzenes with α,β -unsaturated aldehydes by Pd(OAc)₂/HPMoV/O₂ system 275–278
 - enantioselective oxidative coupling of 2-naphthols catalyzed by a novel chiral vanadium complex 267–272
- Oxone[®] 204
- (*α,S,R*)-2,2-[oxybis(ethylene)dioxy]6,6'-[(propylene)dioxy]biphenyl, synthesis of 242–243
- (*S*)-6,6'-[oxybis(ethylene)dioxy]biphenyl-2,2'-diol
- enantioselective enrichment of 244–245
 - synthesis of 243–244
- Pd(OAc)₂/HPMoV/O₂ system 275–278
- perindopril 4, 5
- peroxime proliferator activated receptor (PPAR) agonists 8
- Pfizer
- β -amino acid synthesis 5, 6
 - pregabalin intermediate synthesis 9
- phase transfer catalysts 25–26
- (*R*)-(+)-phenyl benzyl sulfoxide 290–293
- 1-phenyl-3,4-dihydronaphthalene, enantioselective epoxidation of 236–239
- S*-2-phenyl-1,2,3,4-tetrahydroquinoline, synthesis of 172–173
- phenyl-2-(3'-pyridylvinyl) sulfone
- asymmetric epoxidation using polyoleucine hydrogen peroxide gel 251–254
 - synthesis of 252–254
- (*E*)-(2*S*,3*R*)-phenyl-(3-phenyloxiran-2-yl)methanone, synthesis of 249–251
- 3-phenylcyclobutanone, asymmetric Baeyer–Villiger oxidation of 261–263
- 1-phenylethanol, synthesis of both enantiomers 93–97
- (*R*)-1-phenylethanol, synthesis of 95–97
- (*S*)-1-phenylethanol, synthesis of 95
- phenylisoserine taxol unit 22
- phenylphosphinylimine, ATH of 19
- phosphinite oxazoline iridium complexes 42–48
- 2-(phosphinophenyl)pyridine ligand, synthesis of 256–263
- polyoleucine oxidation 26
- polyoleucine-hydrogen peroxide gel 252
- polystyrene-bound chiral RuTsDPEN catalysts 141, 142, 143
- praziquantel (PZQ) 18
- pregabalin intermediate, synthesis of 9
- primary alcohols
- copper (II) catalyzed oxidation of 183–187
 - typical procedure for the oxidation to aldehydes 185–187
- privileged structures 4
- proline catalyzed α -aminoxylation, of aldehydes and ketones 194–199
- proline catalyzed direct asymmetric α -aminoxylation, of ketones **198**
- (*α,S,R*)-6,6'-[(propylene)dioxy]biphenyl-2,2'-diol, synthesis of 240–241
- quinolines, general procedure for the transfer hydrogenation of 170–171
- racemic sulfoxides, kinetic resolution 290–293
- ragaglitazar Dr Reddys 8
- reduction
- asymmetric reduction of ketones 87–159
 - of carbon-carbon double bonds 3–12
 - imine reduction and reductive amination 161081
 - ketone and imine 12–23
- Rh(I)-catalyzed hydrogenations **92**, 93
- Rh(I)-(*R,R*)-2,3-bis(*tert*-butylmethylphosphino)quinoxaline 71–73
- asymmetric hydrogenation of dehydroamino acid esters and α -enamides catalyzed by **72**

- rhodium-catalyzed asymmetric hydrogenation of prochiral amino acid and amine derivatives, (*R,R*)-2,3-bis(*tert*-butylmethylphosphino) quinoxaline as a ligand for 65–73
- rhodium-catalyzed asymmetric hydrogenation of indoles 73–86
- (*S*)-2,2'-bis{[di(4-methoxyphenyl)phosphinyl]oxy}-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl as ligand for 36–41
- [Rh(*R*-Xyl-P-Phos)(COD)]BF₄, preparation of the stock solution of 63–64
- Robinson's catalyst 187–188
- Ru-TsDPEN, preparation of polymer-supported 141–154
- Ru-TsDPEN catalyzed transfer hydrogenation reaction, of β,γ -unsaturated- α -ketoesters 139–141
- Ru/Silia Cat*TEMPO(*c*)-mediated oxidation, of alkenes to α -hydroxyacids 199–204
- [RuBr₂(*S*)-DIFLUORPHOS], synthesis of *in situ* generated 129–131
- [RuBr₂(*S*)-SYNPHOS], synthesis of *in situ* generated 129–131
- [RuCl(*S*)-DIFLUORPHOS](*P*-CYMEME)]Cl, synthesis of 126
- [RuCl(*S*)-SYNPHOS](*P*-CYMEME)]Cl, synthesis of 125–126
- Ru(II)-*N*-arenesulfonyl-1,2-diphenylethylenediamine complexes, preparation of 114
- [RuI(*S*)-DIFLUORPHOS](*P*-CYMEME)]I, synthesis of 127
- Ru(*P*-CYMENE)(TsDPEN), synthesis of 138–139
- sasolidine 17, 18
- secondary alcohols
- 2-iodoxybenzoic acid for selective oxidation of 188–192
 - solvent-free dehydrogenation in the absence of hydrogen acceptors using Robinson's catalyst 187–188
- Sharpless chiral epoxidation, of allyl alcohols 23
- Shi epoxidation catalysts 24
- Silia*Cat*TEMPO (*c*), synthesis of 199–201
- sodium 4-[(ethoxycarbonyl)methoxy]benzenesulfonate 145
- 2,2-spirocyclohexane-4,5-diphenyl-2*H*-imidazole, synthesis of 137
- squalamine 177
- stereoselective catalytic oxidation, of aryl methyl sulfides 300–302
- sulfides
- asymmetric oxidation 288–293
 - benzyl-4,6-*O*-isopropylidene- α -D-glucopyranoside, 2-deoxy-2-[[[(2-hydroxy-3,5-di-*tert*-butylphenyl)methylene]imine], as ligand for vanadium-catalyzed asymmetric oxidation of 293–296
- direct oxidation by an osmate-molecular oxygen system 279–283
- oxidation of 279–302
- selective oxidation to sulfoxides and sulfones using hydrogen peroxide in the presence of zirconium tetrachloride 283–288
- sulfoxides
- chiral 28–29
 - oxidation of 279–302
- sulindac intermediate 28
- SYNPHOS, as ligand for ruthenium-catalyzed hydrogenation of alkenes and ketones 125–132
- tesaglitazar 8
- tetrahydroquinolines, enantioselective synthesis of 170–175
- tetralones 13
- (*R*)-2,2',6,6'-tetramethoxy-bis[di(3,5-dimethylphenyl)phosphino]-3,3'-bipyridine [(*R*)-Xyl-P-Phos], as ligand for rhodium-catalyzed asymmetric hydrogenation of α -dehydroamino acids 55–65
- (\pm)-2,2',6,6'-tetramethoxy-bis[di(3,5-dimethylphenyl)phosphinoyl]-3,3'-bipyridine, optical resolution of 61–62

- 2,2',6,6'-tetramethoxy-bis[di(3,5-dimethylphenyl)phosphinoyl]-3,3'-bipyridine 60
- RAC*-4,4',6,6'-tetramethyl-2,2'-bis[bis(3,5-dimethylphenyl)phosphino]-biphenyl, synthesis of 106–107
- RAC*-4,4',6,6'-tetramethyl-2,2'-bis[bis(3,5-dimethylphenyl)phosphinoyl]-biphenyl, synthesis of 105
- thioanisole, oxidation of 295–296
- thioethers, asymmetric oxidation of 288–290
- tipranavir intermediate synthesis 7, 8
- titanocene-catalyzed reduction, of acetophenone in the presence of water 98–99
- titanocene-catalyzed synthesis, of methyl-4-deuterio-4-phenyl-4-hydroxybutanoate 99–100
- N-p*-toluenesulfonyl-1,2-diphenyl-1,2-ethylenediamine 138
- transfer hydrogenation active catalyst species 17
- TRICHICKENFOOT ligand 5, 6
- TRICHICKENFOOTPHOS 6, 9
- tris[(2-ethylhexanoyl)oxy]borohydride, synthesis of 177
- TRISPHAT 236
- Ulose 204
synthesis of 206–208
- α,β -unsaturated aldehyde reduction 10–12
- unsaturated aldehydes
Bakers' yeast reduction of 11
organocatalytic reduction of 11
- β,γ -unsaturated α -ketoesters, selective reduction of carbonyl group by transfer hydrogenation with Ru(*P*-CYMENE)(TsDPEN) 135–141
- α,β -unsaturated esters, catalytic asymmetric epoxidation of 246–248
- unsaturated nitriles 9–10
- β,γ -unsaturated- α -ketoesters, Ru-TsDPEN catalyzed transfer hydrogenation reaction of 139–141
- vanadium complexes
catalytically oxidative coupling of 7-alkoxy-1-naphthols by chiral 271–272
synthesis of chiral 270–271
- vanadium-catalyzed asymmetric oxidation of sulfides, benzyl-4,6-*O*-isopropylidene- α -D-glucopyranoside, 2-deoxy-2-[[[(2-hydroxy-3, 5-di-*tert*-butylphenyl)methylene]imine], as ligand for 293–296
- vinyl sulfones, examples of the epoxidation of 253
- VO(acac)₂/TBHP
catalyzed epoxidation of 2-(3,7-dimethyl-octa-2,6-dienyl)-phenol 212–213
oxidative cyclization of 2-(2-alkenyl)phenols 212
- VO(acac)₂/TBHP/TFA, oxidative cyclization of 2-(3,7-dimethyl-octa-2,6-dienyl)-phenol 213–214
- WALPHOS 7
- WO₃–30 % H₂O₂–Cinchona alkaloids 288–293
- xemilofiban 5
- Xyl-P-PHOS 55
- (*R*)-XYL-P-PHOS 62–63
- XYL-TetraPHEMP 101–113
- (*R*)-XYL-TetraPHEMP, synthesis of 108–110
- (*S*)-XYL-TetraPHEMP, synthesis of 108–110
- [(*R*)-XYL-TetraPHEMP RuCl₂ (*R,R*)-DPEN], synthesis of 110–111
- [(*S*)-XYL-TetraPHEMP RuCl₂ (*S,S*)-DPEN] as a precatalyst for reduction of acetophenone 111–113
synthesis of 110–111
- yttrium-(*S*)-6,6'-[oxybis(ethylene)dioxy]biphenyl-2,2'-diol 239
- ZD3638 28
- zirconium tetrachloride, selective oxidation of sulfides to sulfoxides and sulfones using hydrogen peroxide in the presence of 283–288